CDRH Turns In Strong Performance For Premarket Reviews In Fiscal Year 2001
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of Device Evaluation maintained 510(k) total review times near statutory timelines in fiscal year 2001, despite the increasing strain on center resources.
You may also be interested in...
Novacept NovaSure To Compete With Ethicon In U.S. Menorrhagia Market
The relatively short procedure time required for endometrial ablation with Novacept's NovaSure device will prove a key advantage over other menorrhagia treatment systems, the firm maintains.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.